Account
Inquiry
Tirzepatide, also known as LY3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is developed for the treatment of type 2 diabetes and has shown significant efficacy in glucose control and weight loss compared to other treatments like Dulaglutide. With a greater affinity for GIP receptors, tirzepatide mimics natural GIP actions, contributing to reduced hyperglycemia.
This peptide features a molecular formula of C225H348N48O68 and appears as a white powder. It is supplied in vials, with packaging options of 10mg per vial and 10 vials per box. The product has a high purity level of 99.9%, making it suitable for research applications focused on metabolic studies and pharmaceutical development.
Clinical trials, such as SURMOUNT-1, have demonstrated that tirzepatide can lead to substantial weight loss—averaging 15% to 20.9% over 72 weeks depending on dosage. It is administered once weekly and has received FDA Fast Track designation for obesity treatment, highlighting its potential in weight-related health issues.
For optimal storage, keep tirzepatide in a cold, dry, and dark place to maintain stability. Avoid repeated freezing and thawing, overexposure to air, light, and long-term storage in solution. Aliquot according to experimental requirements to ensure integrity and effectiveness.
This product is intended for research use only and not for personal consumption. It is ideal for laboratories and institutions focusing on diabetes and obesity research.
